Hawaii Biotech, Inc. (Honolulu, HI), has been  notified by the United States Food and Drug Administration (FDA) that it may  initiate a 24 patient safety study in healthy human volunteers with its  recombinant, subunit West Nile vaccine. The  trial will be conducted at a single site in Hawaii, which the company currently expects  to start in April 2008. Depending on the actual start date, results of the  trial may be available by the end of 2008.

  There is currently no vaccine  for the prevention of West Nile disease in humans, a disease that has caused  over 25,000 cases of disease and over 1,000 deaths since it was introduced in  the US  in 1999.

News

Hawaii Biotech, Inc., (Honolulu, HI), has been notified by the United States Food and Drug Administration (FDA) that it may initiate a 24 patient safety study in healthy human volunteers with its recombinant, subunit West Nile vaccine.